查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全身性紅斑性狼瘡市場報告：至2030年的趨勢、預測與競爭分析
市場調查報告書
商品編碼
1356928

全身性紅斑性狼瘡市場報告：至2030年的趨勢、預測與競爭分析

Systemic Lupus Erythematosus Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全身性紅斑性狼瘡的趨勢與預測

預計到2030年，全球全身性紅斑性狼瘡市場預計將達到 28 億美元，2024年至2030年年複合成長率為 6.6%。這個市場的主要促進因素是自體免疫疾病的盛行率不斷上升，公眾對發炎自體免疫疾病的認知不斷提高以及全球老年人口的增加。全球全身性紅斑性狼瘡市場前景廣闊，零售藥局、醫院和線上藥局市場蘊藏商機。

全身性紅斑性狼瘡市場洞察

  • Lucintel 預測，口服藥物，包括易於給藥的小分子藥物，通常用於治療 SLE，並且患者的偏好不斷增加，在預測期內將繼續成為最大的細分市場。
  • 由於人們越來越偏好購買處方藥，醫院預計在預測期內仍將是該市場的最大細分市場。
  • 由於其強大的醫療基礎設施和主要企業的存在，北美仍然是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個細分市場將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球全身性紅斑性狼瘡市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球全身性紅斑性狼瘡市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類別分類的全球全身性紅斑性狼瘡市場
    • NSAID
    • 抗瘧疾藥
    • 皮質類固醇
    • 免疫抑制劑
    • 生技藥品
  • 按給藥途徑的全球全身性紅斑性狼瘡市場
    • 口服
    • 靜脈
    • 皮下
  • 全球全身性紅斑性狼瘡市場，依最終用途
    • 零售藥房
    • 醫院
    • 網路藥房
    • 其他

第4章 2018-2030年市場趨勢及預測分析，依地區

  • 全球全身性紅斑性狼瘡市場依地區分類
  • 北美全身性紅斑性狼瘡市場
  • 歐洲全身性紅斑性狼瘡市場
  • 亞太全身性紅斑性狼瘡市場
  • 其他區域全身性紅斑性狼瘡市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球全身性紅斑性狼瘡市場成長機會，按藥物類別
    • 全球全身性紅斑性狼瘡市場成長機會，按給藥途徑
    • 全球全身性紅斑性狼瘡市場成長機會，依最終用途
    • 全球全身性紅斑性狼瘡市場成長機會，依地區
  • 全球全身性紅斑性狼瘡市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球全身性紅斑性狼瘡市場的產能擴張
    • 全球全身性紅斑性狼瘡市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Roche
  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Astra Zeneca
  • Novartis
簡介目錄

Systemic Lupus Erythematosus Trends and Forecast

The future of the global systemic lupus erythematosus market looks promising with opportunities in the retail pharmacy, hospital, and online pharmacy markets. The global systemic lupus erythematosus market is expected to reach an estimated $2.8 billion by 2030 with a CAGR of 6.6% from 2024 to 2030. The major drivers for this market are increasing incidence of autoimmune diseases, rising public awareness regarding inflammatory autoimmune disorders, and growing number of geriatric population in worldwide.

A more than 150-page report is developed to help in your business decisions.

Systemic Lupus Erythematosus by Segment

The study includes a forecast for the global systemic lupus erythematosus by drug class, route of administration, end use, and region.

Systemic Lupus Erythematosus Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • NSAIDs
  • Antimalarials
  • Corticosteroids
  • Immunosuppressants
  • Biologics

Systemic Lupus Erythematosus Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Intravenous
  • Subcutaneous

Systemic Lupus Erythematosus Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies
  • Others

Systemic Lupus Erythematosus Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Systemic Lupus Erythematosus Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies systemic lupus erythematosus companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the systemic lupus erythematosus companies profiled in this report include-

  • Roche
  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Astra Zeneca
  • Novartis

Systemic Lupus Erythematosus Market Insights

  • Lucintel forecasts that oral will remain the largest segment over the forecast period due to its growing preference among patients as it includes small molecule medications that are easy to administer and remains commonly used treatment for SLE.
  • Within this market, hospital will remain the largest segment over the forecast period due to growing preference for this facility to purchase prescribed drugs.
  • North America Will remain the largest region due to existence of robust healthcare infrastructure and presence of key players in the region.

Features of the Global Systemic Lupus Erythematosus Market

  • Market Size Estimates: Systemic lupus erythematosus market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Systemic lupus erythematosus market size by drug class, route of administration, end use, and region. in terms of value ($B).
  • Regional Analysis: Systemic lupus erythematosus market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administrations, end uses, and region.s for the systemic lupus erythematosus market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the systemic lupus erythematosus market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the systemic lupus erythematosus market size?

Answer: The global systemic lupus erythematosus market is expected to reach an estimated $2.8 billion by 2030.

Q.2. What is the growth forecast for systemic lupus erythematosus market?

Answer: The global systemic lupus erythematosus market is expected to grow with a CAGR of 6.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the systemic lupus erythematosus market?

Answer: The major drivers for this market are increasing incidence of autoimmune diseases, rising public awareness regarding inflammatory autoimmune disorders, and growing number of geriatric population in worldwide.

Q.4. What are the major segments for systemic lupus erythematosus market?

Answer: The future of the systemic lupus erythematosus market looks promising with opportunities in the retail pharmacy, hospital, and online pharmacy markets.

Q.5. Who are the key systemic lupus erythematosus market companies?

Answer: Some of the key systemic lupus erythematosus companies are as follows:

  • Roche
  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Astra Zeneca
  • Novartis

Q.6. Which systemic lupus erythematosus market segment will be the largest in future?

Answer: Lucintel forecasts that oral will remain the largest segment over the forecast period due to its growing preference among patients as it includes small molecule medications that are easy to administer and remains commonly used treatment for SLE.

Q.7. In systemic lupus erythematosus market, which region is expected to be the largest in next 5 years?

Answer: North America Will remain the largest region due to existence of robust healthcare infrastructure and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the systemic lupus erythematosus market by drug class (NSAIDs, antimalarials, and corticosteroids, immunosuppressants, and biologics), route of administration (oral, intravenous, and subcutaneous), end use (retail pharmacies, hospitals, online pharmacies, and others)and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Systemic Lupus Erythematosus Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Systemic Lupus Erythematosus Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Systemic Lupus Erythematosus Market by Drug Class
    • 3.3.1: NSAIDs
    • 3.3.2: Antimalarials
    • 3.3.3: Corticosteroids
    • 3.3.4: Immunosuppressants
    • 3.3.5: Biologics
  • 3.4: Global Systemic Lupus Erythematosus Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Intravenous
    • 3.4.3: Subcutaneous
  • 3.5: Global Systemic Lupus Erythematosus Market by End Use
    • 3.5.1: Retail Pharmacies
    • 3.5.2: Hospitals
    • 3.5.3: Online Pharmacies
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Systemic Lupus Erythematosus Market by Region
  • 4.2: North American Systemic Lupus Erythematosus Market
    • 4.2.1: North American Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.2.2: North American Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
  • 4.3: European Systemic Lupus Erythematosus Market
    • 4.3.1: European Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.3.2: European Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
  • 4.4: APAC Systemic Lupus Erythematosus Market
    • 4.4.1: APAC Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.4.2: APAC Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
  • 4.5: ROW Systemic Lupus Erythematosus Market
    • 4.5.1: ROW Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.5.2: ROW Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by End Use
    • 6.1.4: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Region
  • 6.2: Emerging Trends in the Global Systemic Lupus Erythematosus Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Systemic Lupus Erythematosus Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Systemic Lupus Erythematosus Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Roche
  • 7.2: Sanofi
  • 7.3: GlaxoSmithKline
  • 7.4: Pfizer
  • 7.5: Bayer
  • 7.6: Astra Zeneca
  • 7.7: Novartis